These findings, also now recapitulated in various ASS1-deficient cancer cell lines [30,31,32,33], were the first to reveal the landscape of how ASS1 deficiency sensitises to ADI-PEG20 and, critically, how arginine deprivation therapy may be deployed against these malignancies. Here, ASS1 is linked to cancer.